Disclaimer
The alfapump® system is currently not approved in Canada for commercial use. DSR® therapy is still in development and is currently not approved in the United States or Canada. Any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. Sequana Medical makes no claims of safety or effectiveness of the DSR® therapy in the U.S. or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.
We are pioneers in the treatment of drug-resistant fluid overload, a serious and frequent clinical complication in patients with liver disease and heart failure. Fluid overload is a well-recognized problem in these growing diseases, causing severe issues for the large number of patients for whom current medications are no longer effective. These patients can have up to 15 liters of extra fluid in their bodies, leading to significant medical problems including increased mortality, repeated hospitalizations, severe pain, difficulty breathing, and restricted mobility that severely impacts daily life.
Our proprietary approaches, alfapump® and DSR, work with the body to remove this excess fluid. Alfapump is delivering clinical and quality-of-life benefits for patients and reducing costs for healthcare systems. DSR® therapy is still in development and is currently not approved in the United States or Canada. Any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. Sequana Medical makes no claims of safety or effectiveness of the DSR® therapy in the U.S. or Canada.
We are listed on Euronext Brussels (Ticker: SEQUA.BR) and headquartered in Ghent, Belgium.
